Dr. Joel Gabre, MD

Dr. Gabre practices at Columbia Vascular Surgery at Columbia University Irving Medical Center's Herbert Irving Pavilion - Laboratory in New York, New York.

Dr. Gabre's NPI, 1538429972, was assigned on May 19, 2012. Dr. Gabre graduated from University of Maryland School of Medicine - Baltimore in 2012. Dr. Gabre holds New York license 303422.

Dr. Gabre's primary practice is Columbia Vascular Surgery at Columbia University Irving Medical Center's Herbert Irving Pavilion - Laboratory, at 161 Ft Washington Ave - 5th Fl, New York, NY 10032. The practice phone is (212) 305-1028.

Dr. Gabre's primary practice is Columbia Vascular Surgery at Columbia University Irving Medical Center's Herbert Irving Pavilion - Laboratory in New York, New York. Dr. Gabre is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Gabre to 2 more group practices and clinics and 1 medical group, each named with a free account. Dr. Gabre's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gabre practices, 4 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Gabre's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Gabre is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Gabre's licenses on file in 5 states: New York, New Jersey, Pennsylvania, Ohio and Michigan.

Dmand AI lists colonoscopy, gastrointestinal bleeding and hemorrhoids among the conditions Dr. Gabre treats.

CMS data shows 11 Medicare services from Dr. Gabre across 1 procedure code in 2024, for 49 Medicare patients. Medicare paid $1,304 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 49 Medicare patients who saw Dr. Gabre in 2024. The largest group is 65 to 74, with 20 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 49% are also on Medicaid. Their average risk score is 2.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gabre's median patient age at 63, with 64% women.

In 2024, Dr. Gabre wrote 119 Medicare Part D claims for 41 patients. 89% of them were for generic drugs. CMS names the drug for 82 of them, across 4 drugs with 11 or more claims each, at $1,346 in total drug cost. In 2023, CMS named 85 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Gabre for performance year 2024, reported through an alternative payment model (APM). Dr. Gabre accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gabre as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 23 papers to Dr. Gabre, published from 2012 to 2025. 2024 was the busiest year, with 4. The most frequent topics are Esophageal Neoplasms, Organoids and Adenocarcinoma. Dr. Gabre has published most often in bioRxiv. Dr. Gabre's most frequent co-authors are Anil K. Rustgi, MD, Gary W. Falk, MD and Gregory G. Ginsberg, MD.

CMS Open Payments shows 2 general payments to Dr. Gabre from 1 drug or device company from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $48.

Dr. Gabre graduated from University of Maryland School of Medicine - Baltimore in 2012.

Dr. Gabre is in network with 14 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.